ロード中...
Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems
Botulinum neurotoxins (BoNTs) are used extensively as therapeutic agents. Serotypes A and B are available as marketed products. Higher doses of BoNT/B are required to reach an efficacy similar to that of products containing BoNT/A. Advances in our understanding of BoNT/B mechanism of action have aff...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628846/ https://ncbi.nlm.nih.gov/pubmed/28982136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0185628 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|